EFM
ENTA icon

E Fund Management’s Enanta Pharmaceuticals ENTA Stock Holding History

E Fund Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,369
Closed -$203K – 338
2022
Q4 		$203K Sell
4,369
-12
-0.3% -$547 0.02% 303
2022
Q3 		$227K Sell
4,381
-1,939
-31% -$113K 0.02% 281
2022
Q2 		$299K Buy
6,320
+3,430
+119% +$186K 0.03% 232
2022
Q1 		$206K Buy
+2,890
New +$188K 0.01% 290

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

E Fund Management's ENTA Position: Q1 2023 in Review

E Fund Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2023, closing a stake of 4,369 shares — an estimated $203K sold.

E Fund Management first reported a position in ENTA in Q1 2022 and held it in 4 quarters. The position peaked at $299K in Q2 2022. 144 funds tracked by Wall St. Rank hold ENTA as of Q1 2023.

  • E Fund Management reported no remaining Enanta Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • E Fund Management sold 4,369 Enanta Pharmaceuticals shares in Q1 2023, an estimated $203K.
  • E Fund Management first reported a position in Enanta Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • E Fund Management's Enanta Pharmaceuticals position peaked at $299K in Q2 2022.
  • 144 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2023.

Based on E Fund Management's 13F filing for Q1 2023, filed 11 May 2023.